Epeius Biotechnologies’ Tumor Targeted Rexin G Receives FDA Orphan Drug Designation For The Treatment Of Osteosarcoma
Epeius Biotechnologies Corporation announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma.
More: continued here
Filed under: Bones on July 16th, 2008